S'abonner

The value of elevated second-trimester β-human chorionic gonadotropin in predicting development of preeclampsia - 10/09/11

Doi : 10.1016/S0002-9378(97)70512-X 
Adnan M.N. Ashour, MB, BS, Ellice S. Lieberman, MD, DrPH, Louise E.Wilkins Haug, MD, PhD, John T. Repke, MD
Boston, Massachusetts 

Abstract

OBJECTIVE: Our purpose was to investigate the association of an elevated second-trimester serum β-human chorionic gonadotropin concentration with the subsequent development of hypertension in pregnancy and to evaluate its utility as a screening test for preeclampsia.

STUDY DESIGN: We examined 6286 nondiabetic women with singleton pregnancies who, as part of triple-screen testing, had a serum β human chorionic gonadotropin level drawn between 15 and 22 weeks' gestation between November 1, 1991, and November 30, 1994. Medical records of women with hypertension (n = 675) were reviewed, patients with chronic hypertension were excluded, and the remainder were classified as having gestational hypertension (n = 333), mild preeclampsia (n = 110), or severe preeclampsia (n = 84). The β-human chorionic gonadotropin level expressed as multiples of the median adjusted for maternal weight and gestational age was compared between normotensive and hypertensive complicated pregnancies.

RESULTS: In the overall population β-human chorionic gonadotropin levels ≥2.0 multiples of the median during the second trimester were significantly associated with development of hypertension in pregnancy. The rate ratio for development of overall hypertension was 1.6 (95% confidence interval 1.3 to 2.0) and for preeclampsia 1.8 (95% confidence interval 1.3 to 2.6). When stratified by parity, a statistically significant association remained only among multiparous women, for overall hypertension (rate ratio 2.2, 95% confidence interval 1.6 to 3.2) and for preeclampsia (rate ratio 3.4, 95% confidence interval 2.1 to 5.6). Adjusting for confounding factors did not alter the results. In the overall population, with the use of 2.0 multiples of the median of β-human chorionic gonadotropin as a cutoff value, the sensitivity of β-human chorionic gonadotropin as a screen for development of hypertension was 15.6%, the specificity was 90.0%, and the positive predictive value was 12.8%.

CONCLUSION: Overall, second-trimester serum β-human chorionic gonadotropin levels were elevated among women who had hypertension during pregnancy. In our population this association was statistically significant only among multiparous women. The utility of an elevated second-trimester β-human chorionic gonadotropin level as a screening test for preeclampsia is limited.(Am J Obstet Gynecol 1997;176:438-42.)

Le texte complet de cet article est disponible en PDF.

Keywords : β-human chorionic gonadotropin, gestational hypertension, preeclampsia


Plan


 From the Division of Maternal-Fetal Medicine and the Department of Obstetrics and Gynecology, Brigham and Women's Hospital and Harvard Medical School.
 Reprint requests: John T. Repke, MD, Brigham and Women's Hospital, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, CWN 584.4, 75 Francis St., Boston, MA 02115.
 6/1/78132


© 1997  Mosby, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 176 - N° 2

P. 438-442 - février 1997 Retour au numéro
Article précédent Article précédent
  • Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: A comparative trial of mifepristone-misoprostol versus surgical abortion
  • Beverly Winikoff, Irving Sivin, Kurus J. Coyaji, Evelio Cabezas, Xiao Bilian, Gu Sujuan, Du Ming-kun, Usha R. Krishna, Andrea Eschen, Charlotte Ellertson
| Article suivant Article suivant
  • Herpes simplex virus type 2 detection by culture and polymerase chain reaction and relationship to genital symptoms and cervical antibody status during the third trimester of pregnancy
  • Kim A. Boggess, D.Heather Watts, Ann C. Hobson, Rhoda L. Ashley, Zane A. Brown, Lawrence Corey

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.